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Background: While most gynecologic cancers respond to first-line cytotoxic chemotherapy, treatment of recurrent
disease is frequently associated with acquired drug resistance. In order to find an in vitro surrogate of this clinical
phenomenon, a tumor chemoresponse assay was studied.
Methods/Materials: Patients who had tissue submitted for repeated chemoresponse testing were identified through a
retrospective search. Sixty-three patients met inclusion criteria (chemoresponse testing completed at primary diagnosis
and upon recurrence of disease and assays completed ≥90 days apart). The Wilcoxon signed-rank test was used
to compare chemoresponse, represented as a response index (RI), between primary and recurrent measurements.
In a secondary analysis, response was categorized and coded as Responsive = 3, Intermediately Responsive = 2
and Non-Responsive = 1, and the paired t-test was used to compare chemoresponse between primary and
recurrent measurement.
Results: Median time between primary and recurrent tumor testing was 309 days (IQR 208–422). Drugs tested
included carboplatin, cisplatin, docetaxel, doxorubicin, gemcitabine, paclitaxel, topotecan, and combination
carboplatin/gemcitabine and carboplatin/paclitaxel. There were no differences in chemoresponse between primary
and recurrent measurement when chemoresponse was represented by RI scores; although a trend toward increased
resistance to paclitaxel upon recurrence was noted. When chemoresponse was analyzed as a continuous variable
corresponding to categorized response, a significant shift toward increased resistance to paclitaxel at recurrence, and a
marginally significant trend toward increased resistance to carboplatin at recurrence, were observed.
Conclusions: We observed a trend toward increased chemoresistance at recurrence for paclitaxel, and a marginally
significant trend toward increased chemoresistance to carboplatin, but no change in chemoresponsiveness between
primary diagnosis and recurrence of disease for other common chemotherapy drugs, including common second-line
agents such as doxorubicin, gemcitabine, and topotecan.
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It is estimated that in 2014, there were 21,980 new cases
of ovarian cancer with 14,270 deaths [1]. The majority of
patients present with advanced stage disease. While the
majority of women will achieve complete clinical remission
after cytoreductive surgery and platinum-based chemo-
therapy, approximately 30% of ovarian cancer patients do
not have a complete response to front-line platinum-based* Correspondence: bradley.monk@chw.edu
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unless otherwise stated.treatment [2-6]. Furthermore, the majority of ovarian can-
cer patients recur and response rates to second-line treat-
ments are substantially lower. This may be due, in part, to
acquired drug resistance [7]. In the recurrent population,
empiric-based chemotherapy is associated with response
rates ranging from only 5 to 20% with limited progression-
free (PFS) and overall survival (OS) [8-11].
Since recurrence rates for ovarian cancer are high and
the associated toxicity to chemotherapy can be signifi-
cant, knowledge of potential tumor responses to chemo-
therapy a priori could be a useful tool in the selection of
effective chemotherapy for patients with advanced orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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unnecessary toxicity and costs, delay of more effective
treatment, and the potential development of acquired
drug- and cross drug-resistance. An in vitro assay per-
formed before therapy initiation to identify the drug(s)
most likely to be effective for the individual patient
would have clinical utility. Information provided by an
in vitro assay, when integrated with clinical judgment,
could lead to the identification of a potentially more effect-
ive treatment, thus eliminating toxicity due to ineffective
treatments, avoiding a delay in the implementation of ef-
fective treatments, and potentially reducing treatment costs.
Chemosensitivity and resistance assays are currently recog-
nized in the National Comprehensive Cancer Network
(NCCN®) Clinical Practice Guidelines for Oncology for
ovarian, fallopian tube, and peritoneal cancers [12,13].
ChemoFx is a live cell platform-based drug response
marker that was developed to overcome the technical
limitations of earlier generations of chemotherapy sen-
sitivity and resistance assays and to determine chemo-
sensitivity as well as chemoresistance [14]. Studies of
this assay in ovarian cancer indicate that ChemoFx re-
sults are predictive of PFS [15] and OS [16].
There is currently limited information on whether
chemosensitivity changes throughout the course of adju-
vant chemotherapy administration and upon recurrence
of disease. Therefore, the primary objective of this study
is to determine whether in vitro tumor response differs
in metachronous gynecologic cancer specimens collected




Inclusion criteria were as follows: (1) tumor samples were
submitted to Precision Therapeutics, Inc. (Pittsburgh, Pa)
for ChemoFx testing between August 2, 2006 and May 31,
2010; (2) chemoresponse testing was completed at pri-
mary diagnosis and upon recurrence of disease; and (3) as-
says were completed at least 90 days apart. A total of 63
participants met the inclusion criteria. Thirty-six of these
patients were enrolled in the ChemoFx Physician Re-
ported Outcomes (ChemoFx PRO) study. The research
protocol was reviewed by the Copernicus Group Institu-
tional Review Board, and they determined that this study
qualifies as exempt research under 45 CFR §46.101 (b) (4)
before the initiation of the analysis. Existing de-identified
(anonymized) clinical and pathological data were used to
perform the analysis.
ChemoFx
Fresh tumor specimens preserved in McCoy’s medium
were received by the commercial laboratory, usually
within 24 hours of removal. Tumor testing methodswere reported previously [15]. Briefly, tumor specimens
were mechanically disrupted to release and establish
malignant epithelial cells as monolayer cultures. The
tumor sample was then tested against a series of 10 ser-
ial dilutions of each drug or drug combination. The range
of drug concentrations tested for each drug(s) was as fol-
lows: carboplatin (1 μM-500 μM), cisplatin (0.2 μM-
100 μM), docetaxel (0.1 nM-25 nM), doxorubicin (2 nM-
1 μM), etoposide (20 nM- 2 μM), gemcitabine (1 nM- 50
nM), ifosfamide (0.2 μM- 100 μM), paclitaxel (0.2 nM-
0.1 μM), and topotecan (0.4 nM- 0.2 μM), in addition to
combination carboplatin/gemcitabine and carboplatin/pac-
litaxel. Combination drugs were tested as a 1:1 combin-
ation of each drug at each dose, for example, dose 1 of
carboplatin-paclitaxel is dose 1 (1 μM) of carboplatin plus
dose 1 (0.2 nM) of paclitaxel. After an incubation period of
72 hours, the cells were fixed with anhydrous ethanol (95%
fixing grade) and stained with 4’6-diamidino-2-phenylin-
dole (DAPI), a fluorescent DNA stain for imaging the nu-
cleus (Sigma-Aldrich Corp, St Louis, MO, USA). Cells that
remained attached after staining were imaged and counted
using automated cell microscopy and cell-counting soft-
ware. The percentages of cells remaining after drug treat-
ment were used to determine survival fraction (SF =
average cell countdosex/average cell countcontrol), from which
dose–response curves were plotted. Each dose–response
curve was assigned a response index (RI) score ranging
from 0 to 10. The RI score is a metric based on adjusted
areas under the curve (aAUC); greater RI values represent
greater sensitivity. Curves were smoothed using a logarith-
mic curve-fit tool (GraphPad Prism®, LaJolla, CA, USA).
Based on the aAUC score, in vitro tumor response was
then categorized into three groups: responsive (R), inter-
mediately responsive (IR), or non-responsive (NR). The
thresholds for these classifications were established based
on the 25th and 75th aAUC percentiles. Drugs tested in-
cluded carboplatin, cisplatin, docetaxel, doxorubicin, gem-
citabine, paclitaxel, and topotecan, in addition to
combination carboplatin/gemcitabine and carboplatin/
paclitaxel.Statistical methods
The Wilcoxon signed rank test was used to compare
chemoresponse (RI score) between primary and recur-
rent measurement. In commercial reports, tumors are
categorized as R, IR or NR to chemotherapies; we there-
fore completed a second analysis with code correspond-
ing to R = 3, IR = 2 and NR =1, and utilized a two-
tailed Wilcoxon signed rank test to compare chemor-
esponse between primary and recurrent measure-
ment. Statistical significance was set at p < 0.05. All
analyses were performed with SAS (version 9.2; SAS
Institute, Cary, NC).
Table 2 Treatment administered to the subset of patients
enrolled in the ChemoFx (Precision Therapeutics, Inc.,
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The demographic characteristics of the 63 patients who met
inclusion criteria are shown in Table 1. Of the 63 pairs, 44
(70%) were diagnosed with ovarian cancer, 6 (10%) with peri-
toneal cancer, 4 (6%) with fallopian tube cancer, and 9 (14%)
with uterine cancer. Mean age of patients was 59 (±11) years.
The majority of cases exhibited poor tumor grade (grade 3)
and FIGO Stage III. In the subset of patients with known
treatment information (those enrolled in the ChemoFx PRO
study), all were treated with a platinum/taxane combination
for at least one cycle between in vitro chemoresponse testing
of their metachronous tumors. Treatment information in
this subsample is shown in Table 2.
Because specific individual chemotherapy agents or com-
binations of agents tested in the assay were selected by the
treating physician, determination of chemoresponse was
not possible for every drug in each patient. Overall, median
time between primary and recurrent assay testing was
309 days (IQR = 208,422; minimum 91; maximum 680).
When examined using the RI score, no significant dif-
ferences were observed in chemoresponse between pri-
mary and recurrent assay results (Table 3); however, a
trend toward increased resistance was observed for the
drug paclitaxel (p = 0.08). When chemoresponse was ex-
amined using the commercially reported categories, a
significant shift toward chemoresistance were observed
for the drug paclitaxel (p = 0.04) and a marginally signifi-
cant shift was observed for the drug carboplatin (p = 0.06)
(Table 4). There were no statistically significant differences
between primary and recurrent measurement in the
remaining drugs tested.Table 1 Characteristics of patients at diagnosis (N = 63)
Age (years) 59.8 ± 11
Cancer Type





G1 Well 1 (2%)
G2 Moderate 6 (10%)
G3 Poor 24 (38%)








Our results suggest that chemoresponsiveness does not
change between primary diagnosis of disease and recur-
rence of disease for the majority of drugs in patients
with gynecologic cancer who experienced recurrence
within approximately one year. These results are consist-
ent with a large analysis of 334 metachronous pairs of
epithelial ovarian cancer specimens performed by Tewari
et al. Their analysis failed to show a significant difference
in the drug resistance profile of primary tumors and
matched recurrences in the same patient [17]. These
findings, in addition to ours, may be unexpected but not
inexplicable. Furthermore, these results are consistent
with observations of biomarker expression in metachro-
nous pairs of epithelial ovarian cancer. No significant
changes in the expression of MDR1, p53, or HER2 were
noted between primary diagnosis and relapse of disease
in 66 patients [18].
A possible explanation for continued chemosensitivity
following exposure to chemotherapy, as observed in our
primary analysis, has been offered by Tewari et al. TheyTable 3 Chemoresponse assay results (expressed as a








Carboplatin 46 5.59(4.89,6.09) 5.32(4.94,5.80) 0.28
Carboplatin/
Gemcitabine
35 5.71(5.16,6.30) 5.90(5.40,6.36) 0.33
Carboplatin/
Paclitaxel
41 6.17(5.15,6.67) 5.92(5.25,6.29) 0.48
Cisplatin 42 5.40(4.66,5.77) 5.38(4.67,5.68) 0.80
Docetaxel 42 5.26(4.74,5.75) 4.96(4.43,5.42) 0.14
Doxorubicin 49 5.17(4.20,5.58) 5.11(4.56,5.56) 0.82
Etoposide 39 5.49(4.66,6.00) 5.41(4.83,5.84) 0.85
Gemcitabine 48 5.27(4.46,5.55) 5.11(4.68,5.55) 0.64
Ifosfamide 30 5.58(5.32,5.80) 5.68(5.25,5.87) 0.90
Paclitaxel 47 5.59(4.99,6.21) 5.30(4.80,5.74) 0.08
Topotecan 52 5.39(4.65,5.74) 5.20(4.54,5.65) 0.99
Table 4 Chemoresponse assay results (expressed as a
continuous variable corresponding to categorized results








Carboplatin 46 2(1–3) 1(1–2) 0.06
Carboplatin/
Gemcitabine
35 2(1–3) 2(2–3) 0.36
Carboplatin/
Paclitaxel
41 3(1–3) 2(1–3) 0.67
Cisplatin 42 2(1–2) 2(1–2) 1.00
Docetaxel 42 1(1–2) 1(1–2) 0.51
Doxorubicin 49 1(1–2) 1(1–2) 0.89
Etoposide 39 2(1–2) 2(1–2) 0.21
Gemcitabine 48 1(1–2) 1(1–2) 0.33
Ifosfamide 30 2(1–2) 2(1–2) 0.83
Paclitaxel 47 2(1–3) 1(1–2) 0.04
Topotecan 52 1.5(1–2) 1(1–2) 0.70
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may harbor residual tumor in poorly vascularized areas.
Such tumors would be shielded from systemic chemo-
therapy, retain their initial drug responsiveness, and con-
tribute to tumor regrowth and recurrence. Because the
length of time between end of treatment and subsequent
recurrence plays an important role in the development
of drug resistance, [19] it is possible that if we had ex-
amined patients with longer time to recurrence, we may
have observed greater shifts toward increased resistance.
A study conducted by Zajchowski, et al. examined differ-
ences in biomarker expression via immunohistochemical
analysis in primary and recurrent ovarian cancer specimens
over a much longer time interval. In the majority of patients
examined, the interval between treatments was >2 years,
and as high as ≈ 8 year from the primary to last-received re-
current specimen. These patients received between 1–5
prior chemotherapies. Though differences were found in the
expression of certain markers within each matched tumor
pair, overall biomarker profiles for the matched patient spec-
imens were very similar [20]. A study examining a larger pa-
tient population is needed to validate these findings.
A commonly held view is that chemoresponsiveness
may change between primary diagnosis and recurrence
of disease with intervening administration of chemother-
apy. This may be due to the selection and clonal expan-
sion of drug-resistant cells. Indeed, we observed a trend
toward increased resistance to paclitaxel in our primary
analysis, and a significant shift toward increased che-
moresistance for paclitaxel, and a marginally significant
shift toward increased chemoresistance for carboplatin,
when examining change categorically. Although the treat-
ment information was not included in the scope of this en-
tire analysis, many of the patients in this study are assumedto have received platinum/taxane-based treatment as first-
line chemotherapy. This assumption is supported by the
treatment information garnered from the subset of patients
enrolled in the ChemoFx PRO study. Exposure to these par-
ticular drugs may, in part, explain the more evident shift to-
wards resistance observed with carboplatin and paclitaxel
from primary to recurrent tumor (i.e., acquired drug resist-
ance). Notably, there was no evidence for the development
of cross-resistance; we did not observe an increase in resist-
ance at recurrence for common second-line treatment
agents, such as doxorubicin, gemcitabine, and topotecan.
The theory of acquired drug resistance may explain our
results and those of a previous study of metachronous
pairs conducted by Matsuo et al.; paclitaxel resistance was
higher upon recurrence in a sample of 29 epithelial ovarian
cancer patients treated with adjuvant platinum/taxane
therapy. In addition, in a sample of 65 patients, recurrent
surgery after initial cytoreduction was significantly associ-
ated with increased resistance to paclitaxel [19]. Similar in-
creases in paclitaxel resistance in recurrent disease have
been reported in other series [20,21]. Additional studies
have shown limited, albeit, significant increases in carbo-
platin [22] and more commonly, paclitaxel, [22,23] che-
moresistance throughout the course of disease in primary
epithelial ovarian cancer, with no changes in any other
cytotoxic agents examined. Clinically, it has been shown
that while taxanes have activity as later-line agents in ovar-
ian cancer, resistance emerges over time and this increased
resistance is very likely due to intervening therapies [24].
Heterogeneity of drug response is a serious clinical
problem encountered when administering chemotherapy.
Chemoresponse assays may help the physician avoid admin-
istering certain chemotherapeutic agents when a patient’s
tumor is found to be resistant to those agents. Our results
suggest that the chemosensitivity profiles provided by Che-
moFx in the primary setting may be valuable for use in both
the primary and recurrent setting. Since very few patients
undergo a secondary surgery, the opportunity to use results
from tissue collected at initial cytoreduction underscores the
importance of our current findings. The primary setting
may be the physician’s only chance to collect a specimen
and thus chemoresponse results in the primary setting may
be critical to that patient’s future treatment.
The limitations of this study are those inherent to retro-
spective studies, including potential selection biases and
lack of blinding and control groups. We were also limited
in statistical power by a small sample size and short time to
recurrence. Additionally, the use of assay results to guide
chemotherapy treatment may be a potential confounder.
Conclusions
In summary, we observed a trend toward increased che-
moresistance at recurrence for the common first-line gy-
necologic cancer treatment agent paclitaxel, and a
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sistance at recurrence for the first-line gynecologic cancer
treatment agent carboplatin, but no change in chemore-
sponsiveness between primary diagnosis and recurrence of
disease for other common chemotherapy drugs, including
common second-line agents such as doxorubicin, gemcita-
bine, and topotecan. Our results are consistent with clinical
observations and established biologic concepts, suggesting
that an in vitro assay may be a useful tool in both research
and clinical practice. Drug resistance remains a major obs-
tacle in cancer therapy. Further research is needed to better
elucidate the mechanisms by which tumors acquire drug
resistance and to define the role of chemoresistance assays
in the treatment of gynecologic cancers.
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